What this test measures
HBeAg is a soluble protein released into the blood by actively replicating hepatitis B virus. Although not part of the viral particle itself, it is consistently produced during replication and is one of the most useful markers of viral activity.
The test (ELISA or CLIA) is qualitative — reactive or non-reactive — and reflects whether the virus is in a high-replication state. Quantitative HBV DNA is used alongside for precise viral load measurement.
Why it matters
For the 40 million Indians with chronic HBV, HBeAg status defines the phase of disease and guides treatment timing. HBeAg-positive patients are usually highly infectious and have very high HBV DNA levels. In pregnancy, HBeAg positivity in the mother is associated with >80% mother-to-child transmission risk without intervention, dropping to <5% with timely birth-dose vaccine + immunoglobulin + maternal antivirals.
The AASLD/EASL phases — immune-tolerant, HBeAg-positive chronic hepatitis, inactive carrier, HBeAg-negative chronic hepatitis — all depend on HBeAg, anti-HBe, HBV DNA, and ALT together. HBeAg is also a treatment response marker — seroconversion to anti-HBe is an end-point in many treatment protocols.
How to prepare
No fasting required. The test is usually ordered alongside HBsAg, anti-HBs, anti-HBc, anti-HBe, HBV DNA, and liver function tests.
Markers & reference ranges
Reference ranges below are typical adult values. Your lab's reported range may differ slightly based on the assay platform and patient demographics — always read your report against the range printed on it.
| Marker | Normal range | If low | If high |
|---|---|---|---|
| HBeAg (Index / Reactive-Non-reactive)[1][2] | Non-reactive (Negative) | Non-reactive — HBeAg not detected. Possible scenarios: inactive carrier (low HBV DNA, normal ALT), HBeAg-negative chronic hepatitis (raised HBV DNA + ALT), or resolved infection. HBV DNA and ALT clarify. | Reactive — active HBV replication. Most patients have high HBV DNA and are highly infectious. Treatment depends on ALT and disease phase. In pregnancy, antivirals (tenofovir) are usually offered in the third trimester. |
HBeAg + companion markers — chronic HBV staging
| Phase | HBeAg | Anti-HBe | HBV DNA | ALT | Management |
|---|---|---|---|---|---|
| Immune-tolerant | Positive | Negative | Very high | Normal | Monitor every 6 months |
| HBeAg-positive chronic hepatitis | Positive | Negative | High | Raised | Antiviral treatment |
| Inactive carrier | Negative | Positive | <2,000 IU/mL | Normal | Monitor every 6–12 months |
| HBeAg-negative chronic hepatitis | Negative | Positive | >2,000 IU/mL | Raised | Antiviral treatment |
| Resolved infection (HBsAg-negative) | Negative | Positive | Undetectable | Normal | No action |
Frequently asked questions
My HBeAg is positive. Do I need treatment right away?
Not always. If ALT is normal and you are young (immune-tolerant phase), monitoring every 6 months is recommended. If ALT is raised, treatment with tenofovir or entecavir is usually offered. A hepatologist will decide based on the full panel.
How long does HBeAg stay positive?
In untreated chronic HBV, spontaneous seroconversion (HBeAg loss + anti-HBe gain) happens at a rate of 5–10% per year. With antiviral therapy, seroconversion rates are higher.
Does HBeAg positivity mean I will give HBV to my baby?
Without intervention, transmission rates exceed 80% in HBeAg-positive mothers. With timely birth-dose vaccine, hepatitis B immunoglobulin within 12 hours, and maternal antivirals in the third trimester (when HBV DNA is high), transmission can drop to <5%.
Why is HBeAg sometimes negative even when HBV DNA is high?
In HBeAg-negative chronic hepatitis B, the virus carries pre-core or basal core promoter mutations that stop HBeAg production but allow continued replication. This is common in Indian HBV genotype D.
How is HBeAg seroconversion treated as a goal?
In HBeAg-positive chronic hepatitis B, seroconversion to anti-HBe is a major treatment milestone. Most clinicians continue antivirals for at least 12 months after seroconversion before considering stopping (in selected cases).
Can I have a household with HBeAg-positive infection?
Yes — household members are at higher risk and should be screened, vaccinated, and (if non-immune) receive anti-HBs surveillance. Sexual partners need vaccination and barrier protection until both are confirmed.
Is HBeAg used as a screening test?
No — HBsAg is the screening test. HBeAg is ordered only after a positive HBsAg, as part of chronic HBV staging.
Related Hepatitis tests
Tests commonly ordered alongside HEPATITIS B ENVELOPE ANTIGEN (HBEAG), or that help interpret an unexpected result.
Sources & references
- AASLD HBV Guidance 2018 · accessed 2026-05-30T00:00:00.000Z
- EASL 2017 Clinical Practice Guidelines on HBV · accessed 2026-05-30T00:00:00.000Z
- CDC — Hepatitis B Serology · accessed 2026-05-30T00:00:00.000Z
- WHO — Hepatitis B Fact Sheet · accessed 2026-05-30T00:00:00.000Z
Book with Zelnoo
Get your HEPATITIS B ENVELOPE ANTIGEN (HBEAG) test done at home — transparent prices, NABL-accredited labs.
Zelnoo lets you compare diagnostic test prices across NABL-accredited labs in Mumbai & Thane, book a free home phlebotomist visit, and receive digital reports in 24–48 hours into a consent-first report vault. No subscriptions, no membership fees — pay only for the test you book.
Book HEPATITIS B ENVELOPE ANTIGEN (HBEAG) now